The inaugural Microbiome Movement – Maternal and Infant Health Summit has been established to improve your understanding of the fundamental maternal-infant microbiome mechanisms of action and advance translation of this causality into evidence-based and clinically validated therapeutic, nutritional and preventative solutions that will configure healthy foundations of the microbiome within the first 1000 days of life.
This first-of-its-kind event is your opportunity to learn from the expertise of key opinion leaders from large pharma, biotech and academic research institutes presenting the latest case studies and in-depth discussion on key topics including:
- Discovering the causal relationships between the maternal-infant microbiome and disease onset
- Exploring different therapeutic products that restore the infant microbiome, as well as treat and prevent disease
- Discussing study design for investigation of the microbiome in maternal and pediatric settings
- Understanding the role of the maternal microbiome in preterm birth and infant health outcomes
- Optimizing –omics and realizing how to integrate these data with novel pre-clinical modelling to generate clinically meaningful results
- Explaining regulatory processes for IND-approved products targeting maternal and infant populations
- Addressing public health, economic and educational considerations for commercializing microbiome-based products for mothers and infants
There is no question that the pre-, peri- and postnatal maternal and infant microbiomes are critical windows of opportunity, that need to be acted upon today.
Join us to unlock the therapeutic potential of the maternal-infant microbiome and proactively contribute to healthier clinical outcomes in new-borns brought into the world tomorrow.
Early booking and group discounts apply, start-up and academic rates are available - see the website for details.
Conference and 1 Workshop: USD 2898.0,
Conference Only: USD 2399.0,
Workshop Only: USD 599.0
Speakers: Alessio Fasano, Professor and Director Mucosal Immunology and Biology Research Center, Massachusetts General Hospital, Aurélien Baudot, International Business Development, ProDigest, Ben Callahan, Assistant Professor, NC State University, Bethany Henrick, Director, Immunology and Diagnostic, Evolve Biosystems, Cathryn Nagler, Bunning Food Allergy Professor, University of Chicago, John Colson, Director of Operations, ClostraBio, David Kyle, Executive Chairman and CSO, Evolve BioSystems, Deshanie Rai, Associate Adjunct Professor, Friedman School of Nutrition Science and Policy - Tufts University, Jeff Roberts, Medical Officer, Division of Vaccines and Related Product Applications, OVRR/CBER/FDA, Joseph Petrosino, CEO, Diversigen, Keith Martinez, Postdoctoral Fellow, Dominguez-Bello Lab, Rutgers University, Mark Heiman, CSO, Scioto Biosciences, Meghan Azad, Assistant Professor, Pediatrics and Child Health, University of Manitoba, Nitya Jain, Principal Investigator, Harvard Medical School, Noah Voreades, Consultant, GenBiome Consulting, Ryan Pace, Post-Doctoral Associate, Aagaard Lab, Baylor College of Medicine, Staffan Stromberg, CEO, Infant Bacterial Therapeutics, Tuval Ben-Yehezkel, CEO, Loop Genomics